| To: tuck who wrote (1270) | 11/21/2002 11:38:04 AM | | From: tuck | | | | Trickle thinks this rally is getting very close to done. Accordingly it makes two moves. It sells AFFX for $29. Trickle will reload below $25.
Trickle has noted ABI faces a number of fundamental difficulties. While it remains an important bellwether of the sector, Trickle feels it will have difficulty moving beyond this $22.5 to $23 range any time soon. And that if Trickle is right about a pullback (if not a war-related crash), better entry prices will await it for ABI and others. Accordingly Trickle sells ABI for $22.65.
Cheers, Tuck |
| | Trickle Portfolio | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (2) |
|
| To: nigel bates who wrote (1272) | 11/21/2002 2:14:47 PM | | From: tuck | | | | The whole thing.
I think the macro trickle environment will turn around before that of say, semiconductors, although you wouldn't know that from watching the latter of late. I'd be looking at Trickle bioterror plays as a way of playing both sides (i.e. if one is concerned about a war related end to the rally). So I keep watching BDAL, high P/E and all. They will likely report on their bookings in early January, if the past is any guide.
Cheers, Tuck |
| | Trickle Portfolio | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: tuck who wrote (1271) | 11/21/2002 3:41:36 PM | | From: PuddleGlum | | | | ABI shows a very promising breakout on this chart:
stockcharts.com[PA][DA][F!3!!]&pref=G
I won't argue with your fundamental observations, but the technical picture (given that the breakout occurred before the current rally took on a manic character) looks quite good.
-pg |
| | Trickle Portfolio | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: PuddleGlum who wrote (1274) | 11/22/2002 10:34:28 AM | | From: tuck | | | | Long time followers of this thread may recall my ethical fondness for Xenogen, a company that missed the IPO window a couple of years back. It markets in vivo imaging systems based on firefly luciferase that mean less slaughter of experimental animals (chiefly mice) and continuous monitoring of their condition during preclinical studies. It's still out there, and recently did a deal with MLNM. Meanwhile these other folks seem to have refined the technique a bit. In vivo monitoring of protein-protein interactions would be neat!
>>Published online before print November 18, 2002
Proc. Natl. Acad. Sci. USA, 10.1073/pnas.242594299
Medical Sciences
Noninvasive imaging of protein-protein interactions in living subjects by using reporter protein complementation and reconstitution strategies
R. Paulmurugan *, Y. Umezawa , and S. S. Gambhir *¶||
*Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California Los Angeles-Jonsson Comprehensive Cancer Center, and ¶Department of Biomathematics, University of California School of Medicine, Los Angeles, CA 90095-1770; and Department of Chemistry, School of Science, University of Tokyo, Hongo, Tokyo 113-033, Japan
Communicated by Michael E. Phelps, University of California, Los Angeles, CA, October 2, 2002 (received for review August 25, 2002)
In this study we have developed bioluminescence-imaging strategies to noninvasively and quantitatively image protein—protein interactions in living mice by using a cooled charge-coupled device camera and split reporter technology. We validate both complementation and intein-mediated reconstitution of split firefly luciferase proteins driven by the interaction of two strongly interacting proteins, MyoD and Id. We use transient transfection of cells and image MyoD-Id interaction after induction of gene expression in cell culture and in cells implanted into living mice. Techniques to study protein-protein interactions in living subjects will allow the study of cellular networks, including signal transduction pathways, as well as development and optimization of pharmaceuticals for modulating protein-protein interactions.
--------------------------------------------------------------------------------
||To whom correspondence should be addressed at: Crump Institute for Molecular Imaging, University of California School of Medicine, B3-399A BRI, 700 Westwood Plaza, Los Angeles, CA 90095-1770.
E-mail: sgambhir@mednet.ucla.edu.
www.pnas.org/cgi/doi/10.1073/pnas.242594299<<
Cheers, Tuck |
| | Trickle Portfolio | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: tuck who wrote (1277) | 11/22/2002 5:45:08 PM | | From: keokalani'nui | | | | Yes of course. Congratulations.
Actually I had a snide comment about tech announcing their change of auditors, but became grateful for the 15-minute cooling-off period. |
| | Trickle Portfolio | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: tuck who started this subject | 11/23/2002 9:47:21 AM | | From: nigel bates | | | | Avecia. Just parking a couple of old PRs, as I note they are recruiting for the new facility.
28 February 2002
Avecia Announces US $100 million Biologics Manufacturing Investment
Avecia today announced a US $100m (£70m) investment programme to build one of the world’s most advanced biologics medicines manufacturing facilities. The investment, at Billingham UK, will create 40,000 litres of contract manufacturing capacity for microbially-derived biologics. The first stage is due on stream in 2003 and, on completion in 2005, it will be the largest purpose-built facility of its kind in the world.
The project is a major step in Avecia’s high-growth strategy to generate US $500m (£350m) fine chemicals sector sales by 2005, and for which its biotechnology and pharmaceuticals contract manufacturing businesses are two key drivers.
The project will generate up to 300 new, science-based jobs and further strengthen the importance of the North of England as a UK centre of excellence in biomanufacturing. The investment is expected to create several hundred additional jobs in plant construction, allied and support services.
Biologics are a new generation of medicines, based on natural proteins. They offer improved ways to treat life threatening diseases - such as forms of cancer, diabetes and heart conditions.
Largest investment:
"This is Avecia’s largest single investment since its formation, in mid-1999", commented Avecia vice president for Biotechnology Dr. Kevin Cox. "It will firmly establish Avecia as a global leader in biologics contract manufacturing, with integrated capability on a single site for development, trials and large-scale manufacturing to cGMP standards".
He continued: "The development also reinforces our position as a contract manufacturing partner of choice for the biotechnology industry - complementing our world-leading position in DNA medicines".
Noting that the UK is already Europe’s leader in biotechnology research, Dr. Cox said: "Avecia’s large scale biologics manufacturing facility at Billingham will now establish the UK as a centre for biomanufacturing in Europe".
"Biotechnology is one of the UK’s fastest-growing industries and our new facility at Billingham will also act as a catalyst for growth and development in Northern England of complementary businesses, services and additional biotechnology investments".
Rising demand:
Biologics account for over 20% of all new drug approvals and there are currently over 250 microbially-derived biologic medicines in clinical trials.
Biologics manufacturing is set to continue as one of the fastest growing sectors in fine chemicals. Current capacity is close to full utilization and healthcare industry demand for contract manufacturing of biologics is forecast to more than double - to over US $700m (approx. £500m) - by 2005.
Programme & timing:
The first phase of Avecia’s biologics investment will comprise two 5,000 litre capacity fermentation streams. Each will have independent harvesting and purification suites, giving maximum flexibility to offer multi-product manufacturing. With plant construction starting shortly, first commercial production is due to begin in 2003.
A second phase development will add two 15,000 litre capacity fermenters and their associated purification streams. Scheduled in-service date is 2005, and the completed facility will be able to run four large-scale manufacturing campaigns simultaneously.
The programme is being engineered, procured and project managed by WS Atkins Plc - one of the world’s leading providers of professional knowledge-based consultancy and support services. Architectural services are being provided by Clean Design Ltd. of Stockton.
Extending capabilities:
The investment programme complements Avecia’s existing Advanced Biologics Centre (ABC) at Billingham, opened in 1998, which produces protein-based vaccines and new medicines for early clinical trials, on scales of up to 1,000 litres.
Noting the benefits for Avecia’s customers, Dr. Cox concluded: “The new facilities will enable seamless transfer of early clinical trials campaigns from our ABC facility to larger scale manufacturing for late clinical trials, product launch and long term supply. This will save customers the time, cost and complexity of transferring manufacturing campaigns between different suppliers or sites”.
27 May 2002
Avecia Biotechnology Expands into Mammalian Cell Culture
In a strategic extension to its biotechnology portfolio, Avecia today announced a first stage investment in mammalian cell culture. The company is to create a state-of-the-art cell and tissue culture development suite at its Biologics centre in Billingham, UK.
The move complements Avecia’s large scale capabilities in microbial fermentation, and builds on its strengths in bioprocess creation and development services.
By exploiting the synergies between microbial and mammalian development and manufacturing technologies - especially in molecular biology, separation, purification and analytical sciences - Avecia expects to deliver customer benefits in mammalian process productivity and cost-of-goods.
Due on stream in July 2002, the mammalian cell culture suite will focus on bioprocess development for therapeutic proteins including monoclonal antibodies and non-GMP manufacture up to 100 litre scale. Plans for a cGMP cell culture pilot facility, to manufacture materials for Phase I and Phase II clinical trials, are also well advanced.
Technological advancement in mammalian cell capability through a combination of internal development, collaboration and in-licensing – so offering customers real productivity benefits - is a key part of Avecia’s strategy to build a world leading biotechnology business.
“By applying our deep knowledge in development of cell-based technologies, we will be able to deliver substantial productivity and cost-of-goods benefits to our customers requiring cell culture-derived therapeutics”, said Dr. Kevin Cox, Vice President - Avecia Biotechnology. “In responding to our customers needs in this way, we are further strengthening our biologics development services with initial emphasis on process and manufacturing productivity gains”.
The suite will enable Avecia to apply its widely-recognised development expertise to a wide range of client programmes. These could include establishing a complete development programme from a client’s gene sequence or cell line, through to optimising and validating a client’s existing process to support robust cGMP manufacture.
Avecia’s strategic extension into mammalian cell-culture follows the company’s recent announcement of a US $100m investment in 40,000 litres of new capacity for microbially-derived biologics. Commercial production is due to begin in 2003 and, on full completion in 2005, the facility will be the largest of its kind in the world. |
| | Trickle Portfolio | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
